KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.

Billal Musah Obeng, Jolie Hutchinson, Ansari Shaik, Ploenchan Chetchotisakd, Iskandar Azwa, Wahyu Nawang Wulan, Nagalingeswaran Kumarasamy, Marcelo Wolff, José Bruguera, Marcelo Losso, Richard Kaplan, Mariama Sadjo Diallo, Nnakelu Eriobu, Godfrey Musoro, July Kumalawati, Abba Badamasi, Munawaroh Fitriah, Deshinta Putri Mulya, Matthew Law, Gail Matthews, Francesca Di Giallonardo, Anthony Dominic Kelleher, Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) Study Group

Clin Infect Dis 82(4) e693-e704

PMID41482685
PMCIDPMC13131943
DOI10.1093/cid/ciaf739
发表日期2026-01-03
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 8 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1.:CONSORT/入组流程图;Figure 2.:图注未提示 KM 曲线;Figure 3.:CONSORT/入组流程图;Figure 4.:非 KM 图;另有 3 张未列出。
摘要

摘要

BACKGROUND: D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) was a phase 3b/4 randomized clinical trial designed to assess second-line treatment options systematically. This substudy evaluated the distribution of drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy. METHODS: From a total of 826 participants across 14 countries, 727 sequences that covered the PR-RT-INT (700), PR-RT (24), and RT (3) regions were analyzed for drug resistance. Sequences were submitted to the Stanford HIV drug resistance database to detect DRMs and assign subtypes. By adjusting for country and antiretroviral therapy regimen, we assessed the association between DRMs and country and reported DRMs. RESULTS: Subtype C of human immunodeficiency virus type 1 (HIV-1) accounted for most (59.3%) infections. There were extraordinarily high rates of high-level resistance to lamivudine and emtricitabine (both at 88.3%) and for efavirenz and nevirapine (92.8% and 96.8%, respectively). On average, nucleoside reverse transcriptase inhibitor mutations had the highest occurrence across countries with M184V/I detected in 86.2% of the samples, while the highest proportion of nonnucleoside reverse transcriptase inhibitor mutations was K103N at 57.8%. K103N had an increased likelihood of occurrence in African and South American countries (P < .05). Participants with prior exposure to a zidovudine-containing regimen had an increased likelihood of T215F/Y mutations (6.80 [2.59-17.86]), while those with nevirapine/rilpivirine exposure had a decreased likelihood of K103N mutations (0.29 [0.15-0.56]). CONCLUSIONS: The regional specificity of mutations underscores the dynamic nature of HIV-1 drug resistance patterns and the importance of monitoring and understanding local mutation profiles.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(8,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractThis graphical abstract is also available at Tidbit: https://tidbitapp.io/institutional-portal/clinical-infectious-diseases/tidbits/regional-variations-of-rates-and-determinants-of-drug-resistance-mutations-in-people-failing-first-line-therapy-for-hiv-1-a-substudy-from-the-d2eft-phase-3b-4-clinical-trial-b88918af-539b-445c-ac49-187657e52a88/update
非 KM Figure
Figure 1.Flowchart of participant enrollment and sequencing outcomes. Successful sequence outputs included participants who had both PR-RT and INT sequenced to form PR-RT-INT combined (9), PR-RT and INT separately (691), only PR-RT (23), PR and RT sequenced separately (1) and only RT (3). A final dataset of 727 sequences that covered PR-RT-INT (700), PR-RT (24), and RT (3) was used for subsequent analyses.
非 KM Figure
Figure 2.Number of participants across gender and human immunodeficiency virus (HIV) subtypes. Shown is gender distribution of enrolled participants across the 14 countries ( A ) and the HIV-1 subtypes detected ( B ). Phylogenetic analysis with maximum-likelihood algorithm was used to confirm the subtypes across the countries ( C ). The branches are colored by country and the subtypes are indicated to the left. Branch length indicates nucleotide substitutions per site.
非 KM Figure
Figure 3.Reported ART regimen of participants prior to study enrollment. Shown are the 13 different first-line combination ART regimen participants used before enrollment. The proportion of the different ART combinations is shown for each country. Abbreviations: ART, antiretroviral therapy; 3TC, lamivudine; ABC, abacavir; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; NVP, nevirapine; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
非 KM Figure
Figure 4.NRTI and associated drug resistance mutations across countries, subtypes, and prior ART exposure. The proportion of 17 major NRTI-codon site mutations detected across the different countries ( A ) and HIV-1 subtypes ( B ), and prior ART exposure (except for etravirine + tenofovir disoproxil fumarate + emtricitabine with no observation) ( C ) and the level of resistance for each NRTI drug as reported in the Stanford HIV database ( D ). Proportions <0.1 are not shown. Abbreviations: ART, antiretroviral therapy; 3TC, lamivudine; ABC, abacavir; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
非 KM Figure
Figure 5.NNRTI-associated drug resistance mutations across countries, subtype, and prior ART exposure. The proportion of 15 major NNRTI-codon site mutations detected are shown for the different countries ( A ), first-line regimen ( B ), HIV-1 subtypes ( C ), and the level of resistance for each NNRTI drug as reported in the Stanford HIV database ( D ). Proportions <0.1 are not shown. Abbreviations: ART, antiretroviral therapy; 3TC, lamivudine; ABC, abacavir; d4T, stavudine; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nevirapine; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
非 KM Figure
Figure 6.Statistical associations between nucleoside reverse transcriptase inhibitor (NRTI)–associated drug resistance mutations (DRMs) and countries and antiretroviral therapy drug categories. The adjusted odds ratios are illustrated as forest plots for those mutations with significant associations ( P < .05) under a multivariate logistic model to assess the association between DRMs and countries ( A ) and NRTI drug categories ( B ). Abbreviations: ABC, abacavir; CI, confidence interval; d4T, stavudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
非 KM Figure
Figure 7.Statistical associations between nonnucleoside reverse transcriptase inhibitor (NNRTI)–associated drug resistance mutations (DRMs) and country and antiretroviral therapy drug categories. The forest plots show the adjusted odds ratios for mutations that showed significant association ( P < .05) under a multivariate logistic model to assess the association between DRMs and country ( A ) and NNRTI drug categories ( B ). Abbreviations: CI, confidence interval; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine.
非 KM Figure